Published in Hepatitis Weekly, October 24th, 2005
The study may lead to a new treatment standard for the one-third of hepatitis C patients who develop treatment-induced anemia as a result of taking a key medication called ribarvirin. Over 4 million Americans are infected with hepatitis C. The research appeared in Clinical Gastroenterology and Hepatology.
Ribarvin, a common...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.